Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction!

EuroIntervention 2022;18:e267-e268. DOI: 10.4244/EIJ-E-22-00004

Pascal Vranckx
Pascal Vranckx1,2, MD, PhD; Marco Valgimigli3, MD, PhD
1. Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium; 2. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; 3. Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), Lugano, Switzerland
Approximately, one out of five patients with atrial fibrillation (AF) will undergo percutaneous coronary intervention (PCI) or suffer from an acute coronary syndrome (ACS). Considering their concomitant need for sustained oral anticoagulation therapy (OAC), the challenge is to identify the optimal antithrombotic strategy to prevent thrombotic recurrences for these patients.

During the past few years, randomised clinical trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST AF-PCI) have focused on the antithrombotic treatment of patients with AF within the first 12 months after PCI12345. In accordance with their findings, both European and North American guidelines recommend triple antithrombotic therapy (TAT), ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
The myocardial perfusion paradigm: a missing link between patient selection and appropriateness of treatment

Latest news